Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma

Abstract

Introduction: In the treatment of house dust mite (HDM) respiratory allergic disease, allergy immunotherapy constitutes an add-on treatment option targeting the underlying immunological mechanisms of allergic disease. However, for the treatment of HDM allergic asthma, the use of subcutaneous allergy immunotherapy (SCIT) has been limited by the risk of systemic adverse events. Thus, sublingually administered allergy immunotherapy (SLIT) has been investigated as a treatment option with an improved tolerability profile that allows for safer treatment of patients with HDM allergic asthma. Areas covered: In this Drug Profile, we provide a review of the clinical data behind the SQ HDM SLITtablet, which was recently approved for the treatment of HDM allergic asthma and allergic rhinitis by regulatory authorities in several European countries. Expert commentary: The SQ HDM SLIT-tablet is the first allergy immunotherapy to be tested prospectively in patients with asthma, and to favorably modify patient relevant end points such as requirement for inhaled corticosteroid (ICS) or the time to first asthma exacerbation upon ICS reduction, suggesting that SQ HDM SLIT-tablet treatment may contribute to improving overall asthma control.

Allergen desensitization reduces the severity of relapsed alopecia areata in dust‐mite allergic patients

“…We found that AARS scores were improved clinically, in accordance with data from other trials (Figure S2A, Table S7). 21–23 However, because of the small sample size ( n = 3), we did not find significant improvement of EASI scores in patients with AD (Figure S2B, Table S7). During AIT, no treatment‐related serious adverse events (SAEs) were observed.…”

Clinical benefits with 300 IR HDM SLIT tablet in Europeans with house dust mite allergic rhinitis: Post hoc analysis of a large phase 3 trial

“…Various allergen formulations administered either subcutaneously or sublingually (liquid or tablet) have been approved for the treatment of moderate to severe AR with or without controlled allergic asthma induced by HDMs. 12 , 18 , 19 , 20 , 21 , 22 , 23 The 300 index of reactivity (IR) sublingual immunotherapy (SLIT) tablet of D. pteronyssinus and D. farinae extracts (total allergenic activity ratio 1:1) has demonstrated efficacy and safety in adults, adolescents, and children with HDM-induced AR (irrespective of mono- or poly-sensitization status or the concomitant presence of mild asthma) in multinational, double-blind, randomized, controlled trials (RCTs), and has been approved for commercialization in the Asia-Pacific region and Europe. 18 , 22 , 24 , 25 , 26 , 27 , 28 Of these, the most recent, international, phase 3 pivotal RCT confirmed the benefits of a 12-month course of treatment with the 300 IR HDM SLIT tablet versus placebo in a large population of adults and adolescents.…”